Skip to content

Celldex Therapeutics CLDX Ratios & Valuation

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Operating margin-35,688.5%-32,815pp-18,587.7%-15,809pp-9,855.4%-7,984pp-4,053.7%-1,936pp-2,873.5%-194pp
Net margin-32,753.6%-30,388pp-16,737.2%-14,488pp-8,635.8%-7,091pp-3,446.9%-1,637pp-2,366.1%+19.9pp
Returns
Return on equity-48.9%-25.7pp-40.6%-13.8pp-32.4%-2.6pp-27.2%+0.4pp-23.2%+2.2pp
Return on invested capital-55.6%-24.9pp-47%-12.1pp-38.9%-0.8pp-33.3%+0.9pp-30.7%+2.6pp
Efficiency
Asset turnover0.0×0.0×0.0×0.0×0.0×
Liquidity
Current ratio8.9×-12.7×10.5×-8.4×13×-11.3×19.7×-9.7×21.7×-10.1×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Per Share
Book value per share$6.85-35.3%$7.94-31.6%$9.01-24.0%$9.87-19.9%$10.59-25.7%
Valuation
Market capitalization$2.11B+75.2%$1.8B+7.6%$1.72B-23.8%$1.44B-41.1%$1.2B-56.3%
Price / sales2,438.2×+2,279×1,167.4×+929×660.7×+435×248.2×-45.6×159.4×-295×
Price / book4.6×+2.9×3.4×+1.2×2.9×0.0×2.2×-0.8×1.7×-1.6×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Celldex Therapeutics's ratios come from?
Every ratio is computed from Celldex Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.